



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/777,789	02/11/2004	Birgit Oppmann	DX0935KC	4562
28008	7590	03/30/2007	EXAMINER	
DNAX RESEARCH INC. LEGAL DEPARTMENT 901 CALIFORNIA AVENUE PALO ALTO, CA 94304			HAYES, ROBERT CLINTON	
			ART UNIT	PAPER NUMBER
			1649	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)
	10/777,789	OPPMANN ET AL.
	Examiner	Art Unit
	Robert C. Hayes, Ph.D.	1649

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 05 January 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 21-49 is/are pending in the application.
 - 4a) Of the above claim(s) 21-30 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 31-49 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 21-49 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>7/7/04</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election of Group VII (claims cancelled claims 10-14) in the reply filed on 11/8/06 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 21-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 11/8/06.

Note that Rule 1.121 requires listing of all claims and their current status. It appears Applicant intended to cancel all pending claims (i.e., 1-30 versus 1-20). Appropriate correction is required in Applicants' response.

Allowable Subject Matter

2. Claim 32 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 31 & 33-49 are rejected under 35 U.S.C. 102(e) as being anticipated by Chang (U.S. Patent 5,741,772; IDS Ref # AB).

Chang teaches antibodies to their human NNT-1 polypeptide of SEQ ID NO: 2, which is 100% identical to SEQ ID NO: 2 within the instant invention's cytokine complex (cols 17-18). Therefore, Chang's antibodies would specifically bind to the human IL-B60 component of the IL-B60/CLF-1 cytokine complex of the instant invention, because these epitopes are 100% identical (i.e., as it relates to claims 31 & 33). In particular, Chang teaches polyclonal, monoclonal, recombinant, humanized and chimeric antibodies (i.e., col. 17, lines 61-62; as it relates to claims 41-44). Binding fragments thereof include single chain antibodies and Fab fragments (i.e., col. 17, line 59- col. 18, line 1; as it relates to claim 40). Therapeutic compositions are described in col. 18, lines 10-14, which are well known in the art to include the pharmaceutical aqueous carriers, water, saline, or buffers containing such, such as PBS (i.e., as it relates to claims 46-48). Detectably labeled antibodies are described in col. 18, lines 11-14 (i.e., as it relates to claim 45). In that Chang specifically discloses antagonist/inhibitory antibodies, the limitations of claims 37-39 are anticipated (i.e., col. 18, lines 10-11). In that cytokine complexes reasonably and inherently bind to a receptor complex of CNTFR, LIFR and gp130, the

Art Unit: 1649

limitations of claim 39 & 36 are anticipated. In that Chang's population of antibodies would be expected to either aid or inhibit binding of a cytokine complex to its normal receptor complex depending on the epitope to which it binds, the limitations of claims 34-36 & 38-39 are further anticipated; absent evidence to the contrary. Lastly, in that the Chang patent constitutes instructions on use of their stored antibodies, the limitations of a kit are anticipated (i.e., as it relates to claim 49).

Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Robert Hayes whose telephone number is (571) 272-0885. The examiner can normally be reached on Monday through Thursday from 9:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Robert C. Hayes, Ph.D.
March 27, 2007

ROBERT C. HAYES, PH.D.
PRIMARY EXAMINER